Fate Therapeutics: RECLAIM-LN Kicks Off — A Speculative Long Around Upcoming Clinical Readouts
Fate Therapeutics (FATE) is an asymmetric, high-risk long trade that buys into an active clinical calendar: the RECLAIM-LN trial is underway and additional data readouts across SLE and iPSC-NK programs are expected. Market cap sits near $291M with roughly $119M of cash on the balance sheet and negative free cash flow; the stock is thinly supported …